UNLIMITED TURBO SHORT - ELI LILLY & CO | Real-time Bid/Ask 05:00:11 2024-06-27 EDT | ||
| 7.46 EUR / 7.61 EUR | -4.62% |
|
| Current month | -48.53% | ||
| 1 month | -50.84% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 7.56 | -4.30% |
| 24-06-26 | 7.9 | +2.33% |
| 24-06-25 | 7.72 | -9.07% |
| 24-06-24 | 8.49 | -9.20% |
| 24-06-21 | 9.35 | -1.99% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 03:35 am
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC68PX |
| ISIN | DE000PC68PX6 |
| Date issued | 2024-03-25 |
| Strike | 982.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 19 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 24.46 € |
|---|---|
| Lowest since issue | 7.14 € |
| Spread | 0.15 € |
| Spread % | 1.94% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Certificates
- Certificat
